The National Healthcare Security Administration (NHSA) has declared the completion of the expert review process for the 2024 National Reimbursement Drug List (NRDL) adjustments. The NHSA has directed relevant pharmaceutical companies to check the review outcomes on its official website, fuwu.nhsa.gov.cn.
Manufacturers of drugs that have received review outcomes classified as ‘simple renewal’, ‘renegotiation for renewal’, ‘new addition via negotiation’, and ‘new addition via price bidding’ are advised to submit confirmation letters and necessary qualification documents by noon on September 18, 2024. For drugs that are confirmed for participation in negotiations (including ‘renegotiation for renewal’ and ‘new addition via negotiation’) and those confirmed for bidding, the respective manufacturers must submit the required materials by 5:00 PM on September 28, 2024. The NHSA is scheduled to conduct an on-site communication meeting with negotiating/bidding enterprises in Beijing on the afternoon of September 19, 2024. – Flcube.com
